P/E ratio for Summit Therapeutics (SMMT)
P/E ratio as of June 2024 (TTM): -6.50
According to Summit Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.49579. At the end of 2022 the company had a P/E ratio of -8.48.
P/E ratio history for Summit Therapeutics from 2017 to 2020
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -8.48 | 202.68% |
| 2021 | -2.80 | |
| 2019 | -7.54 | -46.4% |
| 2018 | -14.1 | |
| 2015 | -16.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | -15.9 | 144.68% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | -138 | 2,017.45% | 🇺🇸 USA |
 Coherus BioSciences
CHRS | -0.5663 | -91.28% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.